Chronic Myeloid Leukemia

NCI/CALGB trial of Genasense plus Gleevec begins

Published in Drug Week, November 15th, 2002

Genta, Inc., (GNTA), in collaboration with Aventis (AVE), announced the initiation of a new clinical trial that uses its lead anticancer drug, Genasense, in combination with Gleevec (imatinib mesylate; Novartis), in patients with chronic myeloid leukemia (CML).

This multicenter trial will be conducted by a national U.S. cooperative study group, the Cancer and Leukemia Group B (CALGB), and will be sponsored by the U.S. National Cancer Institute, pursuant to Genta's Cooperative Research and Development Agreement (CRADA).

Gleevec was approved in record time in 2001 for the treatment of CML. Despite a large number of early responses, however, resistance...

Want to see the full article?

Purchase this article for only $3.00

We're a pay-per-view site for premium content. If you'd like to purchase this article, it's only $3.00.

Welcome to NewsRx!

Learn more about a six-week, no-risk free trial of Drug Week

Source: Drug Week (2002-11-15)

NewsRx is Social

Top Medical Newsletters

Awards

Best Health/Healthcare Content, 2012
Best Health/Healthcare Content, 2011
Best e-Business Site, 2010
Best e-Business Site, 2009
Best e-Business Site, 2008
Best e-Business Site, 2007
Best e-Business Site, 2006
Best Healthcare Content, 2005
Best Overall Internet Site, 2005
Best Interactive Site, 2005

Facts & Stats

NewsRx also is available at LexisNexis, Gale, ProQuest, Factiva, Dialog, Thomson Reuters, NewsEdge, and Dow Jones.

Google 2010 PageRank: #2 Among Top Health News and Media Publications
Google 2010 PageRank: #2 Among Top Science Publications in Biology/Physiology
Google 2010 PageRank: #2 Among Top News and Media for the Business of Pharmaceuticals
Amazon's Alexa 2010 PageRank: #2 News and Media Site for the Pharmaceutical Industry